SYS-CON MEDIA Authors: Kevin Benedict, Jason Bloomberg, David H Deans, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

THE MEDICINES COMPANY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $150,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against The Medicines Company - MDCO

NEW ORLEANS, LA -- (Marketwired) -- 04/01/14 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 22, 2014 to file lead plaintiff applications in a securities class action lawsuit against The Medicines Company (NASDAQ: MDCO), if they purchased the Company's securities during the period between February 20, 2013 and February 12, 2014, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of New Jersey.

What You May Do

If you purchased shares of Medicines and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850, or email KSF Managing Partner Lewis Kahn ([email protected]) or KSF Partner Melinda Nicholson ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 22, 2014.

About the Lawsuit

Medicines and certain of its executives are charged with issuing a series of materially false and misleading statements during the Class Period, violating federal securities laws.

These false statements and omissions included, in part, that: (i) Medicines's drug candidate Cangrelor, designed to prevent blood clots during heart procedures, did not show superiority to clopidogrel, a competing drug already approved by the U.S. Food and Drug Administration ("FDA"); and (ii) Medicines's clinical trials were unethically and inappropriately administered including by delaying administration of clopidogrel and lowering its dosage.

On February 12, 2014, the FDA voted against approval of Cangrelor for patients undergoing certain cardiac procedures. On this news, the price of Medicines's shares plummeted by more than 11%.

About Kahn Swick & Foti, LLC

To learn more about KSF, whose partners include the Former Louisiana Attorney General, Charles C. Foti, Jr., and other lawyers with significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders, you may visit www.ksfcounsel.com.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.